#Gilead Sciences

Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.

It approved 12 weeks of Gilead Sciences’ Vosevi for the re-treatment of adults with all genotypes of HCV who do not have cirrhorsis.

The FDA has expanded approval of the direct-acting antiviral treatments Sovaldi and Harvoni for adolescents ages 12 and older.

The World Health Organization (WHO) has added a new hepatitis C treatment to its updated 2017 Essential Medicines List.

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

A look at Vosevi, the newest treatment for chronic hepatitis C virus infection for people without cirrhosis or with compensated cirrhosis

On July 18, 2017 the U.S. Food and Drug Administration approved the new Hepatitis C treatment Vosevi to treat adults for all genotypes 1-6

The triple-drug regimen comes in a once-daily single tablet.

Maviret and Vosevi were highly effective and well tolerated in clinical trials.

The fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir provides a good alternative to those who have failed treatment.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

In an analysis of the investigational treatment, cure rates were very high for those without cirrhosis after both 8 and 12 weeks of therapy.

However, eight weeks of sofosbuvir/velpatasvir/voxilaprevir worked as well as 12 weeks of Epclusa for those with genotype 3 and cirrhosis.

A small proof-of-concept study of GS-0976 inhibited de novo lipogenesis (DNL) and reduced liver fat and stiffness.